In this interview we discuss how a short diagnosis-to-treatment interval in newly diagnosed diffuse large B-cell lymphoma is associated with worse outcomes and how this could lead to trials favoring patients with a longer diagnosis-to-treatment interval and better expected outcomes.
Adults with Philadelphia chromosome–negative B-cell acute lymphoblastic leukemia are very likely to achieve complete response with intensive combination induction chemotherapy, according to a retrospective review presented at the ASH Annual Meeting.
Continuous lenalidomide therapy improves outcomes among patients with newly diagnosed myeloma who are not autologous stem cell transplant candidates, according to findings from a large phase III clinical trial.
A single treatment with a second-generation CAR T-cell treatment elicited an overall response rate of 94% in a small study of patients with heavily pretreated multiple myeloma, according to the results of a phase I study presented at the ASH Annual Meeting.
About one-third of patients with previously treated chronic lymphocytic leukemia (CLL) were minimal residual disease negative after 6 months of treatment with the combination of targeted agents ibrutinib and venetoclax, according to the results of the TAP CLARITY study.